GlassScriptPhysician profile
Jesse Machaela Grady
NPI 1801414909
$2,739.33
in general payments reported to CMS, 2019-2025
25 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,361 · 2023: $1,211 · 2024: $15.51 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,377.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $311.74 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $282.90 | 2022-2023 | Rexulti, Abilify Maintena, Nuedexta |
| Lundbeck LLC | $222.84 | 2022-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $213.46 | 2022-2023 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $209.16 | 2022-2023 | |
| Axsome Therapeutics, INC. | $209.07 | 2022-2023 | Auvelity |
| Sunovion Pharmaceuticals INC. | $188.13 | 2022 | |
| Bausch Health US, LLC | $132.41 | 2022-2023 | Aplenzin |
| Supernus Pharmaceuticals, INC. | $128.75 | 2023-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $127.64 | 2022-2023 | Lybalvi, Aristada |
| Intuitive Surgical, INC. | $120.65 | 2022 | |
| Neurocrine Biosciences, INC. | $96.22 | 2022-2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $83.05 | 2022-2023 | Spravato |
| Vanda Pharmaceuticals INC. | $79.79 | 2022-2023 | Fanapt, Hetlioz |
| Avanir Pharmaceuticals, INC. | $71.03 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $69.08 | 2022-2023 | Nuplazid |
| Pfizer INC. | $50.80 | 2025 | |
| Corium, LLC | $31.70 | 2023 | Azstarys |
| Ethicon US, LLC | $18.19 | 2023 | Dermabond, Vistaseal, Ethicon |
| Collegium Pharmaceutical, INC. | $17.19 | 2025 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $16.77 | 2023 | |
| Eisai INC. | $16.53 | 2022 | |
| Tris Pharma INC | $14.60 | 2025 | Dyanavel Xr |
| Almatica Pharma LLC | $14.35 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.28 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Grady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.